NCT02924376

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - (FIGHT-202)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 147 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.

Conditions

• Cholangiocarcinoma

Interventions

Type	Name	Description
DRUG	Pemigatinib	Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy

Timeline

• Start date: 2017-01-16
• Primary completion: 2022-02-01
• Completion: 2022-02-01
• First posted: 2016-10-05
• Last updated: 2025-08-14
• Results posted: 2023-02-23

Locations

120 sites across 12 countries: United States, Belgium, France, Germany, Israel, Italy, Japan, South Korea, Spain, Taiwan, Thailand, United Kingdom

Regulatory

• FDA-regulated drug study